Search

Your search keyword '"Karaseva, N."' showing total 206 results

Search Constraints

Start Over You searched for: Author "Karaseva, N." Remove constraint Author: "Karaseva, N."
206 results on '"Karaseva, N."'

Search Results

16. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

24. 1451P Neoadjuvant and adjuvant pembrolizumab (pembro) + chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Patient-reported outcomes (PROs) from the phase III KEYNOTE-585 study

25. INDICATORS OF INFORMATION LITERACY OF HIGH SCHOOL STUDENTS IN KARAGANDA REGION

33. Limitations and opportunities of cancer treatment in the COVID-19 pandemic

35. LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study

39. 366MO Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study

40. 1401P Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study

46. Lung cancers carrying distinct ALK fusion variants demonstrate similar responsiveness to ALK tyrosine kinase inhibitors

47. 139PD Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)

48. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial

50. P1.03-050 Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial

Catalog

Books, media, physical & digital resources